West Pharmaceutical Services (NYSE:WST) versus Align Technology (NASDAQ:ALGN) Financial Contrast

Align Technology (NASDAQ:ALGN – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

88.4% of Align Technology shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.7% of Align Technology shares are held by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Align Technology has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares Align Technology and West Pharmaceutical Services’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Align Technology 11.83% 15.96% 10.48%
West Pharmaceutical Services 18.81% 21.78% 15.99%

Valuation & Earnings

This table compares Align Technology and West Pharmaceutical Services”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Align Technology $4.03 billion 2.90 $410.35 million $6.87 24.16
West Pharmaceutical Services $3.07 billion 9.45 $493.70 million $8.91 46.82

West Pharmaceutical Services has lower revenue, but higher earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Align Technology and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Align Technology 1 7 8 1 2.53
West Pharmaceutical Services 0 1 13 0 2.93

Align Technology presently has a consensus target price of $193.08, indicating a potential upside of 16.33%. West Pharmaceutical Services has a consensus target price of $424.67, indicating a potential upside of 1.79%. Given Align Technology’s higher probable upside, research analysts plainly believe Align Technology is more favorable than West Pharmaceutical Services.

Summary

West Pharmaceutical Services beats Align Technology on 10 of the 15 factors compared between the two stocks.

About Align Technology

(Get Free Report)

Align Technology, Inc. develops, manufactures and markets digital orthodontic and restorative dentistry products. Its best-known offering is the Invisalign system, which uses a series of custom-made clear aligners to straighten teeth. The company also sells Vivera retainers and iTero intraoral scanners, which support digital dental imaging and treatment planning. Founded in 1997, Align helped popularize clear-aligner orthodontic treatment as an alternative to traditional braces. Its digital dentistry portfolio also includes exocad software, used by dental professionals and laboratories to design dental restorations.

About West Pharmaceutical Services

(Get Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.